Active pulmonary tuberculosis: Role for amikacin in early treatment.

Authors :: Méchaï F
Figoni J
Leblanc C
Gousseff M
Vignier N
Bouchaud O
Source :: Medecine et maladies infectieuses [Med Mal Infect] 2016 Sep; Vol. 46 (6), pp. 318-21. Date of Electronic Publication: 2016 May 24.
Publication Year :: 2016
Abstract: Objective: To evaluate the efficacy of amikacin on sputum conversion during initial sputum smear positive tuberculosis treatment.<br />Material and Methods: Single-center observational cohort study (2012-2013) evaluating time to sputum smear conversion with standard treatment (ST) versus standard treatment+amikacin (IV 15mg/kg/day) for seven days (STamK).<br />Results: Forty-five patients were included. Median time to smear negative samples was 26.5 days (14-56) for the 30 (66.7%) patients included in the ST group and 48 days (19.5-69.5) for the 15 patients (33.3%) included in the STamK group (P=0.76). Time to negative culture was only known for 27 patients (61.4%): 47.5 days (26-58) for 18 patients in the ST group and 40 days (14-77) for nine patients in the STamK group.<br />Conclusion: Despite our small sample size, the addition of amikacin in active tuberculosis treatment did not seem to impact time to smear conversion or period of contagiousness.<br /> (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)